Leukemia and Lymphoma

The researchers called for more work to discover specific exposures in patients with leukemia that lead to infections after treatment ends.

The August issue of The American Journal of Managed Care® (AJMC®) featured research on surprise medical billing policies, social determinants of health, and the value of chimeric antigen receptor T-cell therapies, among other topics. Here are 5 findings from research published in the issue.

Treatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

In a long-awaited national coverage determination decision, CMS said Wednesday that it approved chimeric antigen receptor (CAR) T-cell therapies for Medicare beneficiaries nationwide.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

This week, the top managed care news included HHS laying out a plan for importing certain prescription drugs from other countries; a potential new standard of care for chronic lymphocytic leukemia; 3 insulin makers get subpoenaed over their pricing practices.

President Trump is preparing an executive order that would slash prices on nearly all drugs sold to Medicare; Allergan has recalled certain breast implants following 573 cases of implant-associated anaplastic large cell lymphoma; a study has found 1 in 4 people intend to use antibiotics without a prescription.

Pediatric patients with relapsed or refractory B acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) who were treated with blinatumomab proceeded to hematopoietic cell transplant (HCT) without delay and had limited side effects.

The American Society of Clinical Oncology recently held its annual meeting in Chicago, Illinois. The meeting brought together oncologists, payers, and other stakeholders to discuss the latest updates and therapeutic advances in cancer care. Here are 5 of the biggest takeaways from the meeting.

Results of the CLL14 trial, which were presented today at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois, resulted in the approval of the venetoclax combination for these patients in May.

Researchers have identified a new target in the mitochondria of cancer cells that indicate the potential of a treatment class for certain blood cancers.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

A preliminary study discussed how a vaccine regimen stimulated dendritic cells to attack tumors, which could point to a new way of making immunotherapy effective in cancers that have proved resistant to treatment thus far.

Because brentuximab vedotin is so effective in the relapsed and refractory setting, there has been a lot of excitement around assessing the treatment earlier in Hodgkin lymphoma, explained Alison J. Moskowitz, MD, medical oncologist, clinical director, lymphoma inpatient unit, Memorial Sloan Kettering Cancer Center.

Two abstracts presented at the Transplantation and Cellular Therapy Meetings analyzed the detection of minimal residual disease during and after hematopoietic stem cell transplantation.

Alison J. Moskowitz, MD, medical oncologist, clinical director, lymphoma inpatient unit, Memorial Sloan Kettering Cancer Center, discusses how the standard of care for Hodgkin lymphoma varies based on several different factors.

Patients with hematologic malignancies often receive intensive care at the end of life (EOL), but new research has demonstrated that hospice services and palliative care are associated with significantly improved EOL care quality.

Among older patients with non-Hodgkin lymphoma receiving myelosuppressive chemotherapy, use of primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) increased significantly over the past 20 years.

The approval marks the first non-chemotherapy combination regimen for the treatment of patients with chronic lymphocytic leukemia (CLL).

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Patients with Down syndrome are at an increased risk for developing leukemia, but how much of an increased risk depends on age, explained Irene Roberts, MD, professor of pediatric hematology, MRC molecular hematology unit and pediatrics, MRC Weatherall Institute of Molecular Medicine.

While several associations between constitutional syndromes, such as Down syndrome, and predisposition to cancers have been recognized, recommendations for surveillance or clear association between the 2 are lacking.

A study has found no evidence that bleomycin plus granulocyte-stimulating factor (G-CSF) increases the risk for bleomycin-induced pulmonary toxicity in patients with Hodgkin lymphoma.

Research at the University of Washington is exploring the possibility of triggering one gene to take over the function of another with a common mutation that triggers acute lymphoblastic leukemia.

The dual inhibitor first blocks 2 kinases that are known to aid the growth of malignant B cells, and then it disrupts the microenvironment that supports tumor growth.